During the past decade, Regend Therapeutics conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regend Therapeutics" #1 collaborator was "Regend Therapeutics" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Regend Therapeutics" are "Idiopathic Pulmonary Fibrosis" (1 trials) and "Interstitial Lung Diseases" (1 trials). Many other conditions were trialed in "Regend Therapeutics" in a lesser frequency.

Most popular intervention types in "Regend Therapeutics" are "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Lung stem cells" (2 trials). Other intervention names were less common.

The vast majority of trials in "Regend Therapeutics" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Regend Therapeutics". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Regend Therapeutics, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Regend Therapeutics, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".